NCT01834937View on ClinicalTrials.gov

ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain

TerminatedOBSERVATIONAL
Enrollment

17

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

April 30, 2017

Study Completion Date

April 30, 2017

Conditions
Pain Resulting From Bone Metastases
Interventions
DEVICE

ExAblate MRgFUS (Magnetic Resonance guided Focused Ultrasound Surgery)

Focused Ultrasound Surgery - FUS delivered by ExAblate for the palliation of pain due to bone metastases.

Trial Locations (6)

10065

Weill Cornell Medical Center, New York

22908

University of Virginia, Charlottesville

55905

Mayo Clinic, Rochester

91010

City of Hope, Duarte

94107

University of California San Francisco, San Francisco

94305

Stanford University, Stanford

Sponsors

Lead Sponsor

InSightec
All Listed Sponsors
lead

InSightec

INDUSTRY

NCT01834937 - ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain | Biotech Hunter | Biotech Hunter